VIDEO: IRIS Data reveals common inflammation risk factors in brolucizumab
Click Here to Manage Email Alerts
In this video, Caroline R. Baumal, MD, professor at Tufts University School of Medicine, highlighted data from an IRIS study presented at the virtual American Academy of Ophthalmology annual meeting. Baumal noted one study evaluated the incidence of intraocular inflammation with retinal vasculitis and retinal occlusion with brolucizumab treatments. In a study of over 12,000 eyes using IRIS data, incidence of inflammation was over 2%, especially in patients as female and prior history of cataract inflammation or vascular occlusion, Baumal summarized.
“This is interesting data to help understand who may be at risk with brolucizumab and understand the pathogenesis of reaction,” Baumal told Healio.
Collapse
Ip, MS. Ret15. Presented at: AAO20 Virtual Scientific Program; Nov 13-15, 2020. Presented at: AAO20 Virtual Scientific Program; Nov 13-15, 2020.
Read more about
Click Here to Manage Email Alerts